Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Stock Based Compensation: ₺0.0 Mil (TTM As of Mar. 2026)


IST:ONCSM Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
80 GF Score
Price ₺250.50
GF Value ₺253.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Oncosem Onkolojik Sistemlernayi ve Ticaret AS Stock Based Compensation?

Oncosem Onkolojik Sistemlernayi ve Ticaret AS IST:ONCSM 80 Stock Based Compensation is ₺0.0 Mil as of Mar. 2026. GuruFocus rates IST:ONCSM with a GF Score™ of 80/100 and a GF Value™ of ₺253.18 (Fairly Valued). The stock has 4 warning signs investors should review.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Stock Based Compensation for the three months ended in Mar. 2026 was ₺0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₺0.0 Mil.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Stock Based Compensation Related Terms

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Stock Based Compensation Chart

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IST:ONCSM
80GF Score
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0.0 Mil.

What does a Stock Based Compensation of ₺0.0 Mil mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a Stock Based Compensation of ₺0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Stock Based Compensation too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Stock Based Compensation is ₺0.0 Mil. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Stock Based Compensation compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Stock Based Compensation of ₺0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Stock Based Compensation is ₺0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺253.18, compared to a current price of ₺250.50 — trading 1.1% below its estimated fair value. The current Stock Based Compensation is ₺0.0 Mil. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current Stock Based Compensation is ₺0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued. The current stock price of ₺250.50 is trading 1.1% below its estimated GF Value™ of ₺253.18. GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.

Key valuation signals for IST:ONCSM:

  • Stock Based Compensation: ₺0.0 Mil
  • GF Value™: ₺253.18 vs. price of ₺250.50 (1.1% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description

Address Mutlukent Mah. 1988 Cad. No: 12, Cankaya, Ankara, TUR
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is specialized in the production of equipment and medical devices used in cancer treatment.
80GF Score

Get the complete analysis for IST:ONCSM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺250.50
Price
₺253.18
GF Value